questionText: To ask the Secretary of State for Health and Social Care, if he will make representations to NICE on their decision to no longer offer Enertu for women suffering from metastatic HER2-LOW breast cancer.
answerText: Decisions on whether new medicines should be routinely funded by the National Health Service in England are taken by the National Institute for Health and Care Excellence (NICE) on the basis of an evaluation of a treatment’s costs and benefits. NICE’s met...
heading: Trastuzumab Deruxtecan